問卷

TPIDB > Search Result

Search Result

篩選

List

1Cases

2023-04-01 - 2028-12-31

Phase II

Active
An Open-Label multinational, multicenter study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate to severe atopic dermatitis
  • Condition/Disease

    moderate to severe atopic dermatitis

  • Test Drug

    injective

Participate Sites
7Sites

Recruiting7Sites